Increasing Incidence of Cancer Boosts Opportunities for Companies in Molecular Cytogenetics Industry

Molecular cytogenetics is used as a tool for the examination of chromosomal anomalies and research relating to these anomalies. This technique is chosen over the generic chromosomal banding methods as the old techniques deliver low resolution results and at times escape the detection of various variations. Breakthrough technologies such as aCGH and FISH are expected to provide new dimensions to the research and development projects in the field of molecular cytogenetics. 

According to a report published by Transparency Market Research, the global market for molecular cytogentics is projected to exhibit a CAGR of 23.40% from 2013 to 2019. The market stood at US$0.4 bn in 2012 and is likely to reach US$1.9 bn by 2019. 

How technological advancements fuel demand for molecular cytogentics?

As molecular cytogenetics is more dependable than the other traditional techniques used for the diagnosis of chromosomal abnormalities, the technological advancements in this segment are expected to spur the adoption of this technique in future. Breakthrough technologies such as aCGH and FISH are being considered as priceless tools for the analysis of complex diseases, gene discovery, and gene mapping. These techniques also facilitate the diagnosis of solid molecular tumors and hematological malignancies along with their prognosis. These techniques are also known for their speed, sensitivity, accuracy, and high resolution, which encourage healthcare providers to adopt them. The growing importance of molecular cytogentetics in laboratories has led to further advancements in the technique such as digital imaging and improvement in fluorescence microscopes. The implementation of these techniques in laboratories and diagnostic centers is expected to boost theor emand further in future.  

What factors are expected to drive the adoption of molecular cytogenetics across diagnostic centers and laboratories?

The introduction of advanced technologies in molecular cytogenetics diagnosis is expected to encourage more investments in the research and development projects by non-government and government institutions. As technological advancements increase, more institutions are adopting molecular cytogenetics to get appropriate and cost effective results regarding chromosomal anomalies. 

The rising incidences of cancer globally have also led to the adoption of molecular cytogenetics for its diagnosis. The growing awareness about chromosomal abnormalities among people and their inclination towards personalized medicines are also projected to drive the demand for molecular cytogenetics diagnosis. 

Browse Press Release:

http://www.transparencymarketresearch.com/pressrelease/molecular-diagnostics-market.htm

However, the easy accessibility of medical reimbursement policies and lack of transparency may hinder the growth of the molecular cytogenetics market in future. 

North America held the largest share in the global molecular cytogenetics market followed by Europe in 2012. The growing number of research laboratories in these regions is the major factor fuelling demand for molecular cytogenetics. Asia Pacific is projected to emerge as the fastest developing market for molecular cytogenetics due to rising population in the region. The leading companies in the market are entering into collaborations to carry out more researches in the segment. The key players operating in the molecular cytogenetics market are Abbott Laboratories, Oxford Gene Technology, Agilent Technologies, Bio-Rad Laboratories, and Illumina Inc.

Government Support Crucial for Widespread Adoption of Stem Cell Therapy

Stem cells are a type of human cells that give rise to the various types of cells found in the human body. Stem cells hold the potential to evolve into various types of human tissue, which has led to a growing acknowledgement of the obvious medical potential of this property. Stem cell therapy is becoming increasingly common in the treatment of various diseases and the increasing research in the field is expected to further drive the medical applications of stem cells in the coming years.

According to Transparency Market Research, government support is expected to be crucial in the global stem cells market’s expected rise from a 2013 valuation of US$26.3 bn to a valuation of US$119.5 bn by 2018. The market is expected to exhibit a robust 24.2% CAGR between 2012 and 2018.

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

What are the major advances in the field of stem cells and their medical application?

In July 2016, a joint Dutch-Canadian research effort succeeded in discovering a viable method of increasing the amount of stem cells obtained from cord blood. Cord blood, which is blood from the placenta, contains a relatively small amount of stem cells per unit. The method formulated in the research allows researchers to increase the amount of stem cells obtained from cord blood, making this is a crucial advancement in the field of stem cell therapy. 

The team discovered that mirR-125a, a microRNA, is responsible for the property of stem cells to self-renew. This genetic ‘switch’ remains activated in stem cells but is inactivated in the progenitor cells formed from the division of stem cells. Success in activating this switch would result in self-sustaining production of stem cells, which will be a major boost for the global stem cell therapy market.

In April this year, a research team at McMaster University in Hamilton, Ontario, discovered the protein responsible for the growth and development of blood stem cells. The Musashi-2 protein could be the key to helping thousands of patients of various blood disorders, as understanding the ambit of the protein could allow researchers to increase the number of viable stem cells available for therapeutic use.

What are some of the major drivers for the stem cells market?

The key driver for the global stem cells market is the increasing government support across the world. As widespread incorporation of stem cell therapy allows a nation to significantly improve the overall healthcare scenario, countries in North America and Western Europe have provided solid support to stem cell research. The acceptance of stem cell therapy in emerging regions is still lagging behind due to the lack of advanced medical infrastructure to adopt stem cell therapy, but the steady improvement of the healthcare sector in countries such as India and China is likely to be a major growth driver for the global stem cells market.

The increasing prevalence of neurodegenerative disorders is another major driver for the global demand for stem cells. Neural tissue can’t be regenerated or replaced as easily as structural tissues, and the ability of stem cells to develop into human cells provides the perfect avenue for treatment of neurodegenerative conditions.

Introduction of RNA Analysis Tools and Services to Open Huge Business Prospects in Transcriptomics Technologies

There has been a shift in the focus of pharmaceuticals companies towards targeted therapeutics. This has created a demand for disease-specific biomarkers, which in turn has created opportunities in commercializing transcriptome research outcomes. Transcriptome analysis tools and services help identify novel and potential drug targets. 

Since long, the transcriptomes of stem cells and cancer cells have held the interests of researchers who strive to deeply understand how cellular differentiation or carcinogenesis take place. However, the area of study is expected to expand as researchers are now analyzing the transcriptomes of human embryos, which is expected to be a powerful tool for in vitro fertilization. Transcriptomics is thus, a technology that is continually growing in the field of biomarker discoveries and is extensively used to assess the safety of drugs. 

According to a research report by Transparency Market Research (TMR), the global transcriptomics technologies market will rise from US$1.65 bn in 2012 to US$4.6 bn by the end of 2019 expanding at a healthy CAGR of 15.90% between 2013 and 2019. 

In this blog post, TMR answers three critical questions about the global transcriptomics technologies market:

Q. What are the latest trends in the transcriptomics technologies market?

The transcriptomics technologies market is currently witnessing the partnering of many software companies with life science equipment manufacturers. The partnership is done with a vision to introduce reliable and sophisticated software, which enables easy handling of huge volumes of research data. Thus, it is expected that there will be interdependence between the IT industries and life science equipment manufacturers.

Some of the partnerships and acquisitions between IT companies and life sciences equipment manufacturers include: The acquisition of Ingenuity Systems, Inc., based in the U.S. by Qiagen N.V., has enabled web-based applications to handle the growing volumes of research data. Likewise, DNAStar, Inc., a company headquartered in Madison, has entered into an agreement with Life Technologies Corporation to market its software. 

Another trend, which is emerging in the market, is the mutual collaboration of pharmaceutical companies with research and academic institutions. The outsourcing of research in transcriptomics not only provides a good business opportunity to pharmaceutical companies, but benefits the diagnostic manufacturers as well. Such strategic moves are helping pharmaceutical and in-vitro diagnostics companies to reinforce their business presence and help increase their revenue generation.

Q. What are the challenges that the transcriptomics technologies market is expected to face?

The transcriptomics technologies market is expected to be inhibited by the rising difficulty in the management of complex data. Data complexity increases with the advancements in RNA analysis procedures. For instance, the analysis of the data acquired after the sequencing of multiple transcripts is expected to pose a major concern in transcriptomics research as it generates huge, unmanageable research findings or data. 

Dearth of inefficient data analysis tools will be another challenge impeding the growth of the market. There are very few people who have expertise in the field of transcriptomics technologies. This lack of expertise is preventing the transcriptomics technologies market to grow freely. 

Browse Report: http://www.transparencymarketresearch.com/transcriptomics-technologies-market.html

Q. What does the future hold for transcriptomics technologies?

With the introduction of RNA analysis tools and services, the next generation sequencing platform, huge business prospects are expected to open in transcriptomics research. The increasing demand for precision medicine will lead to a growth in transcriptomics research and also increase the degree of its commercialization. 

The current need for exploiting opportunities in developing novel drug discovery will give rise to assay technologies, multiplexed RNA quantification, and gene expression patterns of specific genes. Thus, the forthcoming era of transcriptomics research is expected to bring rapid advances in the field of drug discovery. As such, the price of new drugs is expected to reduce in the future and most importantly there will be elimination or reduction in the prospect of hypothesis failure. 

Global Cord Blood Banking Services Market Driven by Rising Awareness, Government Support

Cord blood banking refers to blood banks that specialize in storing stem cells from the umbilical cord blood. Cord blood and the stem cells it contains are becoming increasingly important in the global medical scenario due to the ability of stem cells to develop into various types of human cells. This ability has made their use practically imperative in several medical fields that deal with tissue and organ damage. The rising awareness about the utility of cord blood has driven the global cord blood banking services market and will continue to be a major factor in the market’s growth trajectory in the coming years.

According to a market report recently released by Transparency Market Research, the global cord blood banking services market was valued at US$12.4 bn in 2012. Exhibiting a steady 5.60% CAGR from 2013 to 2019, the market is expected to rise to a valuation of US$15.2 bn. 

What are the major drivers for the global cord blood banking services market?

Since cord blood and the stem cells that are a part thereof can only be obtained at the culmination of a pregnancy, making parents more aware of the benefits of cord blood banking has emerged as a major driver for the global market. Several developed countries have been moderately successful in educating a significant part of the population about cord blood banking, which has allowed the market to establish a firm foothold in regions such as North America and Western Europe. Not only is cord blood banking a public good, but having access to cord blood stem cells also increases the chances of the baby’s own successful recovery from various diseases at any point in its life. 

The global cord blood banking services market has also been driven by the rapid technological development observed in the sector, which has led to the process steadily becoming safer and more reliable. This has also been helped by the active role played by various healthcare bodies in spreading awareness about cord blood donation. 

Browse Report: http://www.transparencymarketresearch.com/cord-blood-banking-services.html

Why is it important to support the development of public cord blood banks?

The lack of public cord blood banks on a large scale has held the global cord blood banking services market back. While private cord blood banks store cord blood for use on the individual and their immediate family only, public cord blood banks operate as a network to supply cord blood wherever it is needed – much like a regular blood bank. While private cord blood banks are the more popular type of cord blood banks at present, public banks are expected to steadily increase in number over the next few years due to the growing government support afforded to this field.

Stem cells can help cure some of today’s deadliest and most widely prevalent diseases, such as leukemia, lymphoma, several disorders regarding proliferation of blood, and several congenital disorders. The use of stem cells in treating autoimmune diseases, cardiac diseases, and neurological diseases is also under trial and is likely to come to the fore in the coming years as long as the government support to this sector remains steady.

What are the major regional players in the global cord blood banking services market?

North America dominated the global cord blood banking services market in 2013 and is likely to retain the position over the forecast period. However, Asia Pacific is the market to be for cord blood banking market players in the coming years, as government support to healthcare upgrades is rising in this region and the increasing urban population is becoming both more aware about cord blood banking and capable of paying the relatively high prices of cord blood banking services. As prices level out over the coming years with increasing demand, Asia Pacific could well become the dominant regional market for cord blood banking services.

Reduced Drug Development Costs Steer Pharmaceutical Companies to Develop Companion Diagnostics

Pharmaceutical companies are bearing high costs involved with the development and commercialization of drugs and drug discoveries. Thus, there has been an increased focus by pharmaceutical companies on regulating the costs incurred by means of developing companion diagnostics along with therapeutic drugs. The strategy of co-development allows for the commercial availability of safe and effective drugs and thus, companion diagnostics are expected to materialize as efficient diagnostic tools that will be advantageous for pharmaceutical manufacturers. 

Get Free Sample Research Report: 

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=387

Of late, there has been an increased demand for personalized medicines, which in turn is driving the demand for companion diagnostics, states a research report by Transparency Market Research (TMR). According to the report, the market for companion diagnostics is expected to expand at an 18.1% CAGR from 2013 to 2019.

TMR analysts answer key questions that companies operating in the companion diagnostic market need to ask:

Q. How are companion diagnostics revolutionizing patient care?

Companion diagnostics help eliminate the possibility of side effects by identifying the patients who are most likely to be at risk of several side effects by the use of a particular therapeutic drug.  They identify the patients who are most likely to benefit from a particular therapeutic drug and monitor the response of the patient to a treatment with a particular therapeutic drug. 

Monitoring patients’ response to a medicine is done to enable adjustments in the treatment, for improved effectiveness and safety. For instance, the cobas 4800 BRAF V600 mutation test, which is a companion diagnostic for vemurafenib, helps in the detection of the BRAF V600E mutation in the DNA extracted from human melanoma tissue. Developed by Roche Holdings AG, a Switzerland-based biotech company, the test is intended to be used on selected melanoma patients whose tumors carry the BRAF V600R mutation. 

Q. What are the factors challenging the growth of the companion diagnostics market?

The global companion diagnostics market is hampered to a great extent by prolonged developmental and approval period. The need to have both the drug and the device ready to be launched in the market at the same time, can potentially delay approvals. The delays in approvals of personalized medicines deprive the patients of these medicines for prolonged periods, thus hampering the uptake and sales of companion diagnostics. 

Clinical societies have a huge influence on the acceptance of companion diagnostics by end users. The views and opinions of these societies can affect the market as they impart education by giving biased opinions on their own experience with companion diagnostics. These clinical societies pose as key opinion holders and can alter the preference for companion diagnostics among patients.

Q. What is the progress in the field of companion diagnostics?

Companion diagnostics have been highly successful in the oncology area. This success is encouraging the development of companion diagnostics for other indications such as metabolism disorders, central nervous system (CNS) disorders, and infectious diseases. There have been discoveries of biomarkers for newer indication areas, which is expected to lead to a high growth and increase the revenue generation of the companion diagnostics market.

Case in point, Exosome Diagnostics, Inc. has entered into a collaboration with Takeda Pharmaceuticals International Co. to develop an exosomal RNA sequencing platform for biomarkers. With a goal to develop a platform for serial analysis of gene expression patterns beyond oncology, the analysis of RNAs will provide an innovative tool for patient characterization to select patients. It will then monitor the disease and track the response to the therapeutic drug over the time of the treatment in the patient. This biomarker platform is expected to be an effective therapy for patients not just with cancer but with CNS disorders.

Future of Metabolomics Dependent on Biomarker Discovery and Drug Assessment

Metabolomics is a comprehensive study of metabolites within tissues, cells, organisms, and bio fluids. A metabolite is a substance that is either part of a metabolic reaction or is produced by one. Metabolomics is utilized for data mining and for presenting the functional information of an organism’s physiological nature. It comprises the study of products and substrates of metabolism, which are affected by environmental and genetic factors. The demand for metabolomics is predicted to grow, thanks to the increasing application scope of metabolomics. 

Transparency Market Research (TMR), a market intelligence company, answers a series of questions in order to provide a clearer view of the metabolomics market.

Q. What drivers and impeders will have a major impact on the market dynamics by 2024?

The increasing technological advancements in molecular biology and biochemistry have played a major role in the development of the market for metabolomics. In addition, the enhancement in analytical instruments, analysis software, and data processing have also stimulated the growth of the overall metabolomics field. Furthermore, the increasing support from governments and the increasing research funding globally for the commercialization of various products within metabolomics will also create a positive impact on the growth of the market. 

Metabolomics science is also utilized extensively in drug assessment and biomarker discovery. Hence, the swift development of the biotechnology and pharmaceutical industries is supporting the development of the market for metabolomics. The increasing incidence of chronic degenerative diseases such as cardiovascular diseases and cancer, particularly in emerging nations will also augment the growth of the market in the coming years.

On the other hand, the absence of skilled professionals within metabolomics science is a major factor impeding the development of the market. In addition, the increasing data complexity and the low adoption rate of metabolomics are also amongst the prime factors that may pose a negative impact on the growth of the market. 

Q. How is the increasing usage of metabolomics in life sciences a key opportunity in the market?

Owing to the increasing application areas of metabolomics such as phenotyping of genetically modified plants, determination of gene function, and monitoring responses to abiotic and biotic factors, metabolomics is sought after globally. Metabolomics is utilized for bridging the gap between genotype and phenotype by providing a complete view of the cell functioning. It also helps in the identification of novel alterations within certain metabolites. 

Metabolomics has gained significance as a tool within life sciences owing to it being a relatively precise and faster technique that can be implemented with either a specific focus or in a general manner for gaining new knowledge about biological systems. 

Browse Research Release:

http://www.transparencymarketresearch.com/pressrelease/metabolomics-market.htm

Q. What is impeding the adoption of metabolomic technologies in big pharma companies? What is the predicted future of this discipline?

A number of big pharma companies are still negligent in adopting metabolomic technologies in comparison with genomic and proteomic research. This is due to the lingering uncertainties of the advantages presented by metabolomics owing to the failed genomics and proteomics research programs. However, some recent advancements have successfully dispelled some of these doubts. The key focus of metabolomics is on 20 to 100 different metabolites. Although, this comprises a very small part in comparison to other field of ‘omics,’ this discipline is still excelling in the discovery of biomarkers. For instance, as per a recent publication by the American Association for Cancer Research on Cancer Epidemiology, Biomarkers & Prevention, metabolite profiling is being extensively utilized in the study of prostate cancer in order to identify diagnostic, prognostic, and predictive biomarkers. Hence, such growth opportunities will boost the overall growth of the market in forthcoming years.

Why Post-recession Phase is Promising for Global Biotechnology Market

Current buoyant market situations in the field of biotechnology might make one think that it was immune to the recession. The truth is far from it though, as the global biotechnology market had fallen hard during one of the global economy’s worst of decades. Despite receiving massive government funding in the U.S. and other developed regions, the global biotechnology market did not see the light of day till after 2010. The industry kept shrinking and jobs were still being lost. For example, the biosciences industry in Illinois had been reduced by 3.3% between 2001 and 2008, which made only a little more than 57,000 jobs available in biotech.

Getting back to the current scenario, which is much more uplifting, the global biotechnology market is progressing at a whirlwind 11.6% CAGR between 2012 and 2017. In 2011, this market was valued at US$216.5 bn, which will be almost doubled to US$414.5 bn by the end of this financial year of 2017.

Explaining this phenomenal comeback are the solutions to three critical questions, as answered by market analysts from Transparency Market Research:

Have Funding and Investments Increased Over the Years?

They have. The global biotechnology market is one of the most promising ones we have today, in terms of both returns on investments as well as producing major means of manufacturing, food production, and medicine. This can be witnessed in the U.S. biotech market the most, especially in California. It is the leading state in biotech across the country, but is currently being closely chased by other states such as Maryland, which has shown a 27% jump in employment from 2006 to 2008.

Are Developing Economies in on the Action Too?

They are now. The recent advancements in technology in the global biotechnology market have all made it a lot easier for developing economies such as India, Thailand, and China to adopt biotech processes and research at a faster rate. Other factors that are promoting the proliferation of this market in the Asia Pacific and Latin America regions include the large and ready labor force, the sharp increase in both government and private funding, and the need to increase agricultural yield due to rapidly increasing population densities.

Browse Research Release: 

http://www.transparencymarketresearch.com/pressrelease/global-biotechnology-market.htm

Is There a Way to Peak the Growth Rate Soon?

While the time duration cannot be accurately calculated, it is possible to have near-peak growth rate in major segments of the global biotechnology market in the near future. To do so, the industry needs to take care of several high priority restraints. The topmost factor hindering the growth of the global biotechnology market currently, is the time-to-market taken for biopharmaceutical drugs. It can take as many as 12 years for a drug in the global biotechnology market to reach from the laboratories to the market shelves. Another issue in the global biotechnology market pertains to the unethical methods of conducting clinical trials, as experienced by quite a few biotech firms.

The future of the global biotechnology market can be seen to be based around nanotechnology, stem cell technology, and cell cloning technology. Each field has a major need for biotech experts and is expected to drive this market even faster.

Nanotech to Answer the Call of a Surging Europe Molecular Diagnostics Market

The classification of proteins and nucleic acids within the molecules of a patient’s body samples is commonly termed as molecular diagnostics. This field makes use of genome and proteome analytics through biological markers and creates a complete expression of the genetic code from the samples taken. To do so, the researchers in molecular diagnostics apply a mix of concepts from medical testing to molecular biology. These methods are extremely useful in detecting the early stages of diseases and also to create a healthcare strategy for a patient’s treatment. 

The Europe molecular diagnostics market is a place where researchers are competing to perfect the art of predicting diseases, how they develop, and what drugs will work best on them. This can even include extremely special cases in medicine, including pharmacogenomics, certain cases in oncology, and the typing of human leukocyte antigen.

Why Should Investors Consider the Europe Molecular Diagnostics Market More Seriously?

In simpler terms, any investor trying to attain a chunk in modern medicine only needs to look at the statistics of the Europe molecular diagnostics market. This market was previously valued at US$1.6 bn in 2014. From there, the Europe molecular diagnostics market has skyrocketed onward at a CAGR of 11.4% between 2015 and 2023. By the end of 2023, this market is expected to reach US$4.2 bn. 

There are a myriad of reasons for the proliferation of the Europe molecular diagnostics market, but none more obvious than the need for this market’s growth itself. It is a fact that the number of patients stricken with serious illnesses is increasing across the world. Whether it is due to the rising temperature and pollution levels or simply because of the rising population in certain parts of Europe, the truth remains that this region’s healthcare industry is in dire need of some solid developments in order to support the increasing number of the sick.

How Can Nanotechnology be Used to Better the Europe Molecular Diagnostics Market?

It will work in the same way it has for other fields. The option of using nanotechnology in molecular diagnostics is a fairly recent one, but the gains in development shown by researchers have been tremendous. The use of nanotech to make the lab-on-a-chip has allowed biological testing to be conducted at exponentially faster rates. At the same time, the use of magnetic nanoparticles is becoming common in molecule labeling.

Browse Research Release:
http://www.transparencymarketresearch.com/pressrelease/europe-molecular-diagnostics-market.htm

Where Will the Future of Europe Molecular Diagnostics Market Lie?

Although it is difficult to pinpoint the true utilities of molecular diagnostics in the future, we can draw several accurate conclusions looking at the recent market data and current trends. For instance, the use of molecular diagnostics has so far been the highest in infectious diseases, owing to their high prevalence in Europe, one of the strongest regions in this market from a global perspective. The current socioeconomic scenario shows an increase in the healthcare expenditure of individuals, while the environmental and social issues continue to plague mankind in the form of various diseases. The use of molecular diagnostics will therefore be highly consistent in the treatment of infectious diseases in the near future.

Companies Introducing New Life Science Reagents for Laboratory Research and Diagnosis: A Boon for Global Market

Life science reagents is a market that’s pushing ahead for a complete transformation. That’s because many small-sized and medium-sized organizations are introducing new life science reagents. Life science reagents are products that are used in the pharmaceutical and bioscience industries. Data pulled from a report presented by Transparency Market Research (TMR) states that the global life science reagents market will have a valuation of US$25.73 bn by 2019. The availability of diverse products is expected to propel the global life science reagents market in the near future.

Companies in this space typically boast a wide-ranging product portfolio. For example, Tocris, one of the leading suppliers of novel tools for laboratory research, offers a unique collection of more than 4000 life science reagents including GPCR ligands, ion channel modulators, neurotransmitters, and signaling inhibitors. 

The launch of new products is the only sure way to counter the competition, as companies are increasingly demonstrating. A case in point is eBioscience, a world leader in oncology flow cytometry reagents. The company is introducing its new range of life science reagents for research and diagnostics. Apart from multicolor flow cytometry reagents, eBioscience also offers validated general-purpose lab reagents and recombinant proteins for a thorough biological system analysis. 

In this blog post, TMR answers three important questions about the global life science reagents market:

Q. What factors should one consider while buying life science reagents? 

A. Reliability, accuracy, price, consistency, and ease of use are five of the features considered by consumers while buying life science reagents. And when there are companies offering life science reagents with all these factors, buyers get what they are looking for. Key products within the global life science reagents market are: Polymerase chain reaction, tissue culture, in-vitro diagnostics, electrophoresis, chromatography, flow cytometry, mass spectroscopy, and transfection reagents. 

Amongst all available life science reagents, chromatography reagents are the ones that are used most extensively. At present, they hold the largest share in the global life science reagents market. The extensive use of chromatography reagents in product advancement and biotechnology research procedures has propelled this segment. 

Q. Which factors would drive the growth of the global life science reagents market in the near future?

A. Certainly, the use of life science reagents is on the rise globally due to advancements in technology. Life science reagents include reagents used in pharmaceuticals, biotechnology, and bioscience. Since the past decade, the global life science reagents market has registered swift growth due to the rising application of biotechnology and bioscience in the healthcare sector. The increasing occurrence of various diseases, rising aging population, growth in research and development activities, and the rising mortality rate are some of the factors expected to benefit the global life science reagents market in the near future.

Q. What are the possible challenges that the global life science reagents market would face in future?

A. While the global life science reagents market is set for rapid expansion in the years to come, there is no denying the fact that it has to face certain challenges. Factors such as a lack of skilled labor and high capital investment are expected to be the biggest challenges for the global life science reagents market. Furthermore, the large patent repositories and fewer market players are expected to hamper the growth of the global market for life science reagents. 

Browse Research Release:

http://www.transparencymarketresearch.com/pressrelease/global-life-sciences-reagents-analytical-reagents.htm

Global Market for Reagents, Research Kits and Analytical Instruments for Genomics and Proteomics Gains from Increasing Investments for Research

The global market for reagents, research kits and analytical instruments for genomics and proteomics is witnessing an exponential rise. The increased investments for research activities in the field of medical and healthcare in developing economies are likely to boost this market significantly over the next few years.

The market is also expected to gain traction on account of the rapid increase in the drug discovery and the rising demand for accuracy in the identification of diseases, which are likely to propel the usage of reagents, research kits, and analytical tools in the field of genomics and proteomics in the nearing future.

All these factors indicate towards a healthy future for the global market for reagents, research kits and analytical instruments for genomics and proteomics. However, experts predict the market may face hurdles on account of the high cost associated with these tools and several other factors.

A research study by Transparency Market Research (TMR) estimates the global market for reagents, research kits, and analytical instruments for genomics and proteomics to register a healthy CAGR of 12.10% during the period from 2013 to 2019, reporting a rise from US$23.8 bn in 2012 to US$52.3 bn by the end 2019. In this blog post, TMR answers significant questions about the worldwide market for reagents, research kits and analytical instruments for genomics and proteomics:

What are the key trends influencing the market for reagents, research kits and analytical instruments for genomics and proteomics?

The biggest trend in this market is the integration of suppliers with various research institutes and laboratories to increase research activities in this field. The increasing preference for personalized medicines has propelled the need for the advancement in technologies utilized in genomics and proteomics, which has triggered the need for further research.

Another major trend in this market is the increasing investments from pharmaceutical and biotech companies for the research and development of advanced genomics and proteomics tools.

What are the major challenges in the growth of this market?

A huge disconnect between the discovery of biomarkers and their approval by regulatory authorities is one of the key challenges this market is facing. The low awareness regarding genomics and proteomics in emerging economies, hampering the adoption of these technologies, is also limiting the growth of this market.

Apart from this, the dearth of qualified researchers and the high cost incurred in mandatory training in this field are also expected to restrict this market from reporting a steady rise.

What are the significant trends seen in the competitive landscape of this market?

The global market for reagents, research kits and analytical instruments for genomics and proteomics exhibits a highly fragmented competitive landscape. Major pharmaceutical and biotech players are increasingly involving in mergers, acquisitions, and strategic partnerships with the participants operating in this market in order to venture into it and strengthen their product portfolio.

Browse Research Release: 

http://www.transparencymarketresearch.com/pressrelease/proteomics-market.htm

Recently, Sygnis, a pharma company, announced its plans to acquire Expedeon Holdings, a proteomics reagents and tools manufacturer. After the merger, the Expedeon’s offerings will be added to the SYGNIS’ product portfolio, which is currently focused on next-generation sequencing and molecular biology. The pharma company said that it will fund the deal with around US$5.7 mn from a planned offering of approximately 20.5 million shares.

Ability to Answer Complicated Medical Questions Gives Global Genome Engineering Market a Tremendous Push

From movies to manuals, genome engineering has been a subject of insatiable curiosity for both the geeky lot and scientists who have been closely studying human evolution. However, very few people really understand the complex structure and intricacies of this branch of engineering. 

Q. What Does Genome Engineering Hold for the Future?

A. Optimists believe that genome engineering might have answers to painful cystic fibrosis and helpless Alzheimer's disease. In fact, if rumors could be true, this branch of engineering might just have a fix for blindness, deafness, and baldness. However, this market is struggling with high costs related to building high tech biolabs that are run by exceptionally trained professionals. However, the good news is that global genome engineering market is still ahead of its game as the academics are gradually catching up technological aspects of it. This field of engineering has been growing at an exceptional pace due to the growing number of applications of cell line engineering, animal genome engineering, and plant genome engineering amongst others. In the current scenario, it is playing a pivotal role in finding solutions pertaining to the complications of human health. 

Q. Which Regions Will Lead the Global Genome Engineering Market?

A. According to a research report published by Transparency Market Research, the genome engineering market stood at US$2.20 bn in 2014 and is anticipated to surge at a CAGR of 14.2% from 2015 to 2023. The biggest contributors to this revenue will be North America, Asia Pacific, Europe, and Rest of the World. Out of these, North America will make a significant contribution of and hold about half of market share. Immense government funding for research and development and the strong presence of big companies involved in genome engineering will help North America retain its stance in the coming years as well. The research analysts at Transparency Market Research have also observed that Asia Pacific will expand at a steady pace due generous expenditure on academic research. 

Q. Why will CRISPR Technology Emerge as Leader in Global Market?

A. The technologies used in the global genome engineering market are transcription activator-like effector nuclease (TALEN), clustered regularly interspaced short palindromic repeats (CRISPR), and zinc finger nuclease (ZFN) amongst others. 

The evolution of CRISPR and CRISPR-associated protein 9 (CRISPR-cas9), have created a stir in the field of genome engineering. The CRISPR technology held the dominant share in the overall market in 2014, closely followed by TALEN. Research analysts state that CRISPR technology will grow at the fastest pace in the coming years due its cost-effective and highly precise results. Today, the evolution of the CRISPR method is being utilized for understanding complications of disorders such as sickle-cell anemia, hemophilia, HIV/AIDS, and several other types of cancers. Currently, these techniques are in various stages of clinical development focused towards modifying the genetic material of somatic cells.

Browse Research Release:
http://www.transparencymarketresearch.com/pressrelease/genome-editing-engineering-market.htm

In the near future, the global genome engineering market will show a remarkable rate of progress due to increasing investments, technological developments, and a growing demand for synthetic genes. Advances in CRISPR-Cas9 genome engineering would positively impact future market growth. Researchers and investors will have to devise ways of solving issues related to the ethical impact of genome engineering and its applications in the modification of the human genes, strict regulatory framework, and the negative perception of genetic research to achieve true success.

Epigenetics Drugs and Diagnostic Technologies Market Witnesses Rapid Research and Development of New-generation Diagnostic Technologies

The global epigenetics drugs and diagnostic technologies market has been rising at a significant pace over the past few years due to the emergence of novel drugs and more efficient, next-generation diagnostic technologies. The widespread ongoing research aimed at examining the role of epigenetics in several diseases in humans is the chief factor fueling the market. The global epigenetics drugs & diagnostic technologies market is projected to be worth US$5.7 bn by 2018 according to a recent market research report published by Transparency Market Research.

Epigenetics: A Primer

The term epigenetics refers to the transmissible changes in the expression of genes that does not involve changes to the underlying sequence of DNA molecules. In biological terms, this is a change in phenotype without a change in genotype. This affects how the genes are read by cells. Epigenetic modifications are a regular and natural phenomenon but can also be influenced by a number of factors such as age, lifestyle, environment, and disease state. At least three systems associated with gene silencing, including histone modification, DNA methylation, and non-coding RNA are presently considered to be the key reasons initiating and sustaining epigenetic changes.

Rising Prevalence of Cancer a Major Driver of Market 

Research in epigenetics has significantly expanded in the past few years and, with the increased sophistication of sequencing methodologies, it has become an increasingly important part of the process of exploring new potential therapeutic treatments for cancer and several other diseases that have been linked to aberrant epigenetic modifications.

The rising prevalence of a number of cancers worldwide and the proven benefits of using aberrant levels of DNA methylation (5-mC) and hydroxymethylation (5-hmC) levels as valuable biomarkers for the disease have prompted healthcare bodies in advocating the adoption of epigenetic diagnostic technologies. This factor has also significantly propelled the market for epigenetics drugs.

Some of the most prominent FDA-approved epigenetics drugs that are currently available in the market are Dacogen (decitabine) from Eisai and Vidaza (azacitidine) by Celgene for inhibition of DMNT. The market also features Istodax (romidepsin) from Celegne and Zolinza (vorinostat) by Merck for the inhibition of HDAC and treating Cutaneous T Cell Lymphoma.

EpiGentek’s New-generation Epigenetic Diagnostic Kit Promises Faster and Easier Results 

EpiGentek, a New York-based biotech company specializing in epigenetic research products, has recently launched two new assay kits for ELISA-based assessment of global DNA methylation and hydroxymethylation. The new arrays, as fourth generation technologies of the company’s popular MethylFlash(TM) ELISA kit, have been further refined to enhance accuracy, speed, convenience, and sensitivity. MethylFlash(TM) has been used by researchers since 2005 for studies in epigenetics as a convenient and cost-effective alternative to mass spectrometry and other conventional methylation analysis methods.

The company has stated that the new “one-step” kits eliminate the need for multiple samples and several steps for binding antibodies in traditional ELISA kits, thereby significantly reducing the handling time by 50% as compared to the company’s previous MethylFlash(TM) kits. The new kits are also capable of detecting hydroxymethylated and methylated DNA to the precision level of picograms (10-12g).

Browse Research Release: 

http://www.transparencymarketresearch.com/pressrelease/global-epigenetics-market.htm

Over the course of time, the improved accuracy and speed of such new-generation epigenetic diagnostic technologies can help boost development of the epigenetic drugs and diagnostic technologies. This will help strengthen the capability of epigenetic results in providing evidence to clinical applications, allowing the research to be conducted for the purpose of formulating effective epigenetic drugs. 

Active Role in Cancer Diagnosis and Treatment Spurs Use of Radiopharmaceuticals, Market to Rise Exponentially

Radiopharmaceuticals are a group of pharmaceutical drugs that have radioactivity. They are used for the diagnosis and treatment of various diseases such as tumors, cancers, and diseases affecting the bone marrow, heart, kidney, liver, lungs, salivary gland, and urinary bladder. The radiopharmaceuticals market is expanding owing to the increasing rate of chronic cardiovascular and neurology diseases and will be worth US$12.2 bn by 2018, expanding at a whopping CAGR of 18.3%, according to a report published by Transparency Market Research. 

The spectrum of radiopharmaceuticals is broadening due to the coordinated efforts of chemists, physicians, and manufacturers of synthesis equipment. 

Actinium Pharmaceuticals, Inc. Enters into Agreement with Zevacor Pharma, Inc. for Production of Iomab-B

Actinium Pharmaceuticals, Inc., a biopharmaceutical company that is developing an innovative targeted payload immunotherapeutic to treat advanced forms of cancer, has recently entered into an agreement with radiopharmaceutical products manufacturer Zevacor Pharma, Inc. in the U.S. The two companies have entered the agreement to produce Iomab-B, which is a radioimmunotherapy to be used as an induction and conditioning agent prior to bone marrow transplant. Iomab-B is to be used on patients above 55 years of age who are undergoing treatment for acute myeloid leukemia (AML). 

Iomab-B is a radioimmunoconjugate comprising iodine-131 radioisotope and BC8, which is a novel murine monoclonal antibody. BC8 was developed to target CD45, which is a pan-leukocytic antigen found in the white blood cells. CD45 makes BC8 useful in targeting white blood cells in preparation for the transplantation of the hematopoietic stem cell in a number of blood cancer indications. 

BC8, when labeled with radioactive isotopes, transports radioactivity directly to the location of cancerous growth, thus avoiding side effects of radiation on the healthy tissues. Iomab-B can be used as a conditioning agent on patients suffering from Hodgkin's disease, Non-Hodgkin lymphomas, acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, and chronic myeloid leukemia. 

Such new developments in the field of medical science are expected to drive the radiopharmaceuticals market in future.

Browse Research Release:

http://www.transparencymarketresearch.com/pressrelease/global-radiopharmaceuticals-market.htm

SPECT and PET – The Science of Medical Imaging 

Single photon emission computerized tomography (SPECT) and positron emission tomography (PET) are useful in enabling doctors to determine the presence and size of cancerous tumors. PET and SPECT work on the same principle – that of detecting gamma rays and building a 3D picture of a cancerous tumor. A radioactive tracer, such as glucose with a radioactive isotope, is injected into the patient. As tumor cells grow, they require higher amounts of glucose. Blood carries glucose throughout the body of the patient but it is absorbed mostly by the cancerous or tumor site, absorbing the isotope with it. The isotope then decays, emitting gamma rays. The gamma rays are then collected by the detectors present around the patient, which then builds up a picture of the positions and shape of the tumor, along with where they came from. 

Utilization of a radiotracer in PET and SPECT for imaging has changed the entire process of diagnosis of disease. With rising cases of cancer and tumors and the resultant need to diagnose them effectively, the use of radiopharmaceuticals is only expected to show an upward graph.

Europe Platelet Rich Plasma (PRP) Market Benefits from Celebrities’ Endorsement of the Therapy

Platelet-rich plasma (PRP), also known as blood spinning, is among the class of therapies that heighten the human body’s ability to heal itself faster. Although it started making the headlines only recently, platelet rich plasma therapy has been in use since the 1970s, when it was primarily used in dentistry. 

Here’s how it works: A medical practitioner extracts an ounce or two of blood from an individual’s vein. The blood is then put into a centrifuge and spun so the platelets separate. The platelets are what secrete growth factors that allow blood to clot and the healing process to begin. The spun blood – which is now rich in plasma – is injected back into the individual’s body at the desired site where it helps expedite injured tissue repair. 

With several success stories centered on the use of platelet rich plasma coming to the fore, consumers in Europe are expected to be more open to trying the therapy in a bid to fix orthopedic problems, for aesthetic procedures, and during neurosurgery. The Europe platelet rich plasma market was valued at US$42.1 mn in 2013, says market intelligence firm Transparency Market Research. This market is projected to stand at US$87.2 mn in 2022, registering an 8.3% CAGR between 2014 and 2022.

With Famous Sports Persons Endorsing the Therapy, Europe Platelet Rich Plasma Market Gains Immensely

The most celebrated sportspersons are constantly trying to outdo their best performance. But to do this, they’re also heavily reliant on the use of new treatments that can help them best their previous record – PRP is featuring prominently in the list of therapies that can help them meet this end. 

With platelet-rich plasma being aggressively marketed as a cure-all for sports injuries, it’s not surprising that the treatment is becoming popular among sports persons – from Spanish tennis ace Rafael Nadal to American golfer Tiger Woods to American basketball player Kobe Bryant.

Driven by the proven success of platelet rich plasma in treating various orthopedic conditions, it isn’t surprising that in the Europe PRP market, the demand for the therapy in orthopedic applications was the highest. According to TMR, orthopedic procedures accounted for 38.3% of the Europe platelet rich plasma market in 2013.

Use of Platelet Rich Plasma Therapy Accelerating in Cosmetic Procedures

Facials and other skin treatment procedures that use platelet rich plasma therapy as a base are drawing much attention in the skincare and cosmetic industry. Celebrities such as actor Kim Kardashian, who have undergone PRP therapy foe aesthetic reasons, have encouraged many others across the world to approach dermatologists for similar procedures. 

A platelet rich plasma facial entails the extraction of blood from a person’s arm. The sample is then spun at high speeds in a machine to separate and concentrate the platelets. The plasma thus extracted is applied on a person’s face using extremely tiny needles – a procedure that doesn’t cause much pain or discomfort. Doctors say that this cosmetic procedure helps the skin build greater amounts of elastin and collagen to rejuvenate itself. The use of platelet rich plasma in cosmetic surgeries will thus help drive the Europe PRP market ahead.

Although there have been some reports that PRP hasn’t suited patients (Nadal, for one, said that he had to stop playing tennis for seven months the second time he took PRP as it didn’t work effectively), most patients typically report relief within a few weeks of undergoing PRP therapy. As more trials are conducted to improve the outcomes of platelet rich plasma therapy, the market will continue to surge ahead, not just in Europe but worldwide.

Browse Research Release: http://www.transparencymarketresearch.com/pressrelease/europe-platelet-rich-plasma-industry.htm

Could Europe Outgrow North America in the In Vitro Colorectal Cancer Screening Tests Market?

Colorectal cancer, the third most common type of cancer worldwide, affected 1.4 mn people in 2012, says the World Cancer Research Fund International. In the next nine years (by 2035), the world will have nearly 2.4 mn colorectal cancer patients. Korea was the country with the highest rate of colorectal cancer, followed by Slovakia, Hungary, Denmark, and the Netherlands in the top five. These figures underline the rapid spread of the disease and the need to diagnose it at an early stage so patients can go back to leading a normal life as soon as possible. That has directly impacted the In-vitro colorectal cancer screening tests market, with demand for such tests having surged over the past few years.

A recent market study by Transparency Market Research predicts that the global market for in-vitro colorectal cancer screening tests will hold a US$980.6-mn opportunity by 2023, up remarkably from the market’s worth of US$494.1 mn as of 2014. At an estimated compounded annual growth rate of 7.5% between 2015 and 2023, it is clear that companies in the market will continue to launch new products in response to the rising demand for colorectal cancer screening tests. In vitro screening tests are becoming increasingly popular for many different diseases and conditions. Colorectal cancer is no exception.

European Countries Report High Rates of Colorectal Cancer, but North America In Vitro Colorectal Cancer Screening Tests Market Valued the Highest

The market for in vitro colorectal cancer screening tests in North America was in the leading position in 2014 in terms of revenue. The prevalence of colon cancer in North America is on the rise, thus creating conditions conducive for the growth of this market. Moreover, government policies have been extremely supportive as far as the development and introduction of new, safe in vitro cancer screening tests go. This has given the market in North America a further push. The overall spends on healthcare are high in North America as compared to other regions worldwide – yet another factor contributing to putting North America in the top position in the in vitro colorectal cancer screening tests market.

However, the next few years could well see a change in the status quo because several countries in Europe are reporting a rise in the incidence of colorectal cancer, leading to a proportionate rise in demand for screening tests. The massive graying population here and notable improvements in healthcare infrastructure can be credited for this imminent change. 

Browse Research PR: 

http://www.transparencymarketresearch.com/pressrelease/in-vitro-colorectal-cancer-screening-tests-industry.htm

Demand for Fecal Occult Blood Tests Stays Strong

An uncontrolled growth in the cells of the colon or rectum can lead to colon cancer, also known as colorectal cancer. Advances in screening and testing technologies have made it easier for medical practitioners to determine the presence of colorectal cancer among patients and advise the best course of action to treat it. 

Currently, the key types of in vitro colorectal cancer screening tests that are available on the market can be classed into: stool biomarker tests, fecal occult blood tests, and blood biomarker tests. Of these, fecal occult blood tests are the most commonly used screening tests for colorectal cancer. Their demand is primarily steered by the rising number of diabetics worldwide, the high demand for screening tests that are non-invasive in nature, and the ease of collecting the sample for the test. 

Global Mice Model Market Gains Impetus from Rising Use of Mice Models for Conducting Genetic Research

In the last couple of decades, mouse modelling has emerged as a premier mammalian model system for conducting effective genetic research. Mice models have long remained the basis of fundamental and applied research in life science, and are continuing to exhibit robust growth. Due to the close psychological and genetic similarities between mice and humans, scientists hailing from diverse biomedical fields have gravitated to mice models. Furthermore, the ease with which the genomes of mice can be manipulated and analyzed has also given a boost to the global mice model market.

In its latest report, Transparency Market Research has pegged the overall value of the global mice model at US$1 bn in 2014. The market is projected to reach US$1.7 bn by the end of 2023. If the figures hold true, the global mice model market will exhibit a 6.4% CAGR between 2015 and 2023. Although worms, yeasts, and flies are considered excellent models for scrutinizing the cell cycle and development process, mice have proven to be a far better tool for studying the nervous, skeletal, cardiovascular, endocrine, immune, and other complex physiological systems that mammals share. 

Genetic Similarities of Mice with Other Mammals Boost Market for Mice Model

Like humans and several other mammals, mice often develop diseases that negatively affecttheir immune systems such as cancer, diabetes, oestoporasis, hypertension, glaucoma, and others. Furthermore, certain diseases that affect humans but do not naturally occur in mice, such as Alzheimer’s and cystic fibrosis, can be induced in mice by manipulating their genome to study the effect of novel therapeutics in the treatment of such ailments. The demand for mice model, therefore, increases with the rising funding in research and development to find possible cures for chronic ailments.

Mice present low cost of maintenance and have the ability to multiply rapidly, reproducing as often as nine weeks. This further adds to their appeal as models for biomedical research.

Development of New Therapeutics with Mice Models Propels Mice Model Market

Development of mice models for studying the effects of potential therapeutics in the treatment of certain specific diseases and debilitating health conditions has accelerated tremendously in the last couple of years. The development has been so rapid that mice models have become indispensable in the evaluation of both pipeline and established treatment modalities, particularly in cases of cardiovascular diseases, cancer, neurological disorders, and metabolic anomalies.

Application of mice models in drug discovery enables the development of novel therapeutics strategies, target identification and validation, disease treatment, drug screening, and toxicity and safety screening.

Browse Press Release: 

http://www.transparencymarketresearch.com/pressrelease/global-mice-model-market.htm

Ethical Issues and Stringent Regulations Hinder Global Mice Model Market

The latest advances in genetic engineering that assist in evaluating a drug’s mechanism of action will boost the market for drug discovery. This in turn is likely to fuel demand from the mice model market. However, on the flip side, stringent regulatory frameworks precisely controlling the use of animals for research in laboratories, rising concerns pertaining to animal cruelty, and other ethical concerns related to the use of animals will have an adverse impact on the overall mice model market.

It’s the Big Investment Push for Europe’s Biotech Firms with Immunotherapies in the Spotlight

The biotech sector in Europe at present is witnessing a generous flow of investments from several quarters. This increased funding has given noteworthy impetus to the entire structure of the biotechnology sector in Europe. Numerous biotech firms in Europe are raising funds via public offerings and even secondary offerings. The rates prevailing in the market have exceeded business expectations, thereby marking a whole new beginning in the current century as regards the expected rate of return that the European biotech sector is anticipated to yield. 

But which area of biotechnology will witness the injection of these funds in the European market? It is the area of immunotherapies which is expected to undergo phenomenal development and in-depth R&D. Europe’s biotech sector is anticipated to expand and prosper at a robust rate, a factor sufficient to encourage companies and the public sector to invest voraciously. 

The Impressive Steadfast Performance of the Biotechnology Sector

Amidst the nagging economic crisis in the euro zone, the biotech sector has managed to steer clear of the adverse impact of the same. Also, the year 2000 highlighted the public financing position of the European biotechnology sector with it having raised close to 3 billion euros via initial public offerings and an additional amount of almost 2.5 billion euros via other miscellaneous offerings. The earlier week saw European biotech firms raising funds that exceeded US$1.5 billion in initial public offerings. Recently, Celyad SA, a Belgium-based firm specializing in cell therapy received a fund amount worth US$100 million via IPO.

What’s making this Sector Earn the Big Bucks?

The funds being received by biotechnology firms in Europe are mainly used in developing technologies and mechanisms that enhance the capacity of the human immune system to fight against infections and diseases. Developing such a technique of fighting anomalies is a very novel approach towards treating serious diseases such as cancer because the treatment of such diseases hitherto relied mainly upon the action of antibody-therapies, which only acted on the surface cells.

Any type of novelty or innovation in the biotechnology sector acts as a driving force for institutions to invest and allot funds to. With a bright investment scenario and robust performance of Europe’s biotech sector, the future seems bright with the investment trend continuing in the forthcoming years as well.

U.K.-based Immunocore, a leading biotechnology firm received by far the highest funding from investment management companies such as Eli Lilly and Co. to the tune of almost US$320 million. The company also disclosed that the funds would be mobilized towards ImmTACs, which the company defines as the next-gen cancer treating medicines with the ability to fight tumors which cannot be treated by antibody drugs. Senior officials have stated that this company being the recipient of such huge funds indicates the faith that the public sector and investment bodies have on endorsing such technologies. Also, the funding will play a pivotal role in further research activities pertaining to the IMCgp100 which is a highly advanced drug that is administered in treating melanoma. 

Bone Morphogenetic Proteins Market Expected to Reach USD 587.069 Million Globally in 2022: Transparency Market Research

According to a new market report published by Transparency Market Research “Bone Morphogenetic Proteins Market (Types : rhBMP-2 and rhbmp-7; Applications: Spinal Fusion, Trauma, Reconstructive and Oral- Maxillofacial) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2014 – 2022”, the global bone morphogenetic proteins market was valued at USD 612.601 million in 2013 and is expected to grow at a CAGR of 2.1% during the forecast period from 2014 to 2022 to reach USD 587.069 million in 2022.

Browse the full Bone Morphogenetic Proteins Market Report: http://www.transparencymarketresearch.com/bone-morphogenetic-protein-market.html

To date, autograft bone graft substitutes harvested from the patient’s own body and allografts harvested from human cadaver or animal are considered ideal for healing injured bone tissues. Although, autologus and allogenic bone grafting is an effective treatment of certain spinal disorders, the bone transplantation procedure could prolong hospital stay, increase blood loss, recovery time, risk of infectious disease transmission, and increased stress at the harvest site. Furthermore, autografts are not suitable for elderly patients and allogenic bone grafts in some cases show low bio-activity level. Thus, bone grafting procedures are witnessing a steady shift from allogenic and autologus bone graft substitutes to growth factors such as bone morphogenetic proteins (BMPs) and cell-based matrices. BMPs have the ability to stimulate new bone formation by initiating the differentiation of stem cells into osteoblasts. The BMP products have eliminated the need for bone harvesting and reduced the healing time. Thus, the market for BMPs is increasing owing to better osteoinduction and fusion rate, which have reduced the hospital stay, consequently reducing the overhead expenses.

The global bone morphogenetic proteins market, based on geography, is segmented into North America, Europe, Asia Pacific, and Rest of the World (RoW). In 2013, North America accounted for the majority share of this market globally in terms of revenue and is anticipated to retain its position during the forecast period. Growth in this market is expected to be driven by aging population and the desire to have an active lifestyle. Similarly, increasing incidences of lower back pain, which is commonly observed in people aged between 40 years and 80 years, is also a key factor that is expected to increase the uptake of BMPs in North America. According to the National Institutes of Health statistics, lower back pain was the most common cause of pain, followed by migraine or headache, and neck pain in the U.S. in 2012. Moreover, 28.4% of the population of the U.S. visits physician clinics for chronic lower back pain. Lower back pain is associated common reason for missed work and job-related disability. Thus, patients with back pain are advised spinal fusion procedures, if non-surgical treatment is ineffective. Therefore, growing incidences of lower back pain that requires spinal surgeries is expected to propel demand for bone morphogenetic proteins in North America. Furthermore, in North America spinal fusion surgeries accounted for the largest share of the market at 76.5% in 2013. In addition, according to the Agency for Healthcare Research and Quality (AHRQ), the number of spinal fusion procedures in the U.S. increased by 72% from 2002 (260,000) to 2011 (460,000). The European region followed the North America bone morphogenetic proteins market globally in 2013.

Press Release for Bone Morphogenetic Proteins Market:

http://www.transparencymarketresearch.com/pressrelease/bone-morphogenetic-protein-market.htm

The most promising growth in this market is expected to emerge from the Asia-Pacific region due to rising geriatric population, which is more prone to orthopedic disorders and requires urgent effective care. In addition, the rapidly evolving medical tourism industry in countries such as India, Thailand, and Singapore, rise in disposable income, and growing awareness about orthopedic treatment are few key reasons that are anticipated to propel growth of the BMP market in this region. The BMP market in RoW is underdeveloped and has not expanded due to high cost, reimbursement challenges, and inadequate training of surgeons. Adverse side effects associated with BMP usage have also restricted the uptake of BMPs in these regions.

The market for bone morphogenetic proteins is emerging and is currently occupied by only two players, Medtronic plc and Olympus Biotech Corporation. Of the two, in 2013 Medtronic held the lion’s share due to wide usage of INFUSE. On the other hand, Olympus Biotech accounted for less than 7% of the global BMP market. This is because OP-1/Opgenra is approved for cases, where autologus bone marrow harvesting is not possible or other treatments have failed.

The global bone morphogenetic proteins market is segmented by type as follows:

o  Global Bone Morphogenetic Proteins Market Revenue, by Types

o     rhBMP-2

o     rhBMP-7

o  Global Bone Morphogenetic Proteins Market Revenue, by Application

o     Spinal Fusion

o     Trauma

o     Reconstructive Surgery

o     Oral-Maxillofacial

o  Global Bone Morphogenetic Proteins Market Revenue, by Geography

o     North America

o   Types

o   Applications

o     Europe

o   Types

o   Applications

o     Asia Pacific

o   Types

o   Applications

o     RoW

o   Types

o   Applications

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket Ghumare

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/